All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The MUC1 glycoprotein is a transmembrane epithelial mucin normally expressed on the apical surface of most simple glandular epithelial cells. In tumors, MUC1 is overexpressed and distributed all over the cell surface, aberrantly glycosylated, and shed in the tissue microenvironment. MUC1 expressed by breast cancer carries shortened O-glycans such as GalNAca1-O-Ser/Thr (Tn) or Galh1-3GalNAca1-O-Ser/Thr (T, core 1), which may be sialylated to give sialyl-Tn or sialyl-T. Tn glycoform of MUC1 (Tn-MUC1) is a neoantigen interconnected in various tumors. Hostile to Tn-MUC1 CAR T cells exhibited target-specific cytotoxicity and effectively controlled tumor development in xenograft models of T cell leukemia and pancreatic growth.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-LC128 | Anti-Tn-MUC1 (237) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 237 | Mouse | scFv-CD28-CD3ζ | Lentiviral | T cell | ||
CAR-LC129 | Anti-Tn-MUC1 (237) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 237 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | ||
CAR-ZP3078 | Anti-Tn-MUC1 (5E5) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 5E5 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP3079 | Anti-Tn-MUC1 (5E5) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 5E5 | Humanized | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP3080 | Anti-Tn-MUC1 (3H4 ) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 3H4 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-ZP3081 | Anti-Tn-MUC1 (3H4 ) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 3H4 | Humanized | scFv-41BB-CD3ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION